Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Brainstorm Cell Therapeutics Stock

BCLI
US10501E2019
A12BXW

Price

0.42
Today +/-
+0
Today %
+0 %
P

Brainstorm Cell Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Brainstorm Cell Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Brainstorm Cell Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Brainstorm Cell Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Brainstorm Cell Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Brainstorm Cell Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Brainstorm Cell Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Brainstorm Cell Therapeutics’s growth potential.

Brainstorm Cell Therapeutics Revenue, EBIT and net profit per share

DateBrainstorm Cell Therapeutics RevenueBrainstorm Cell Therapeutics EBITBrainstorm Cell Therapeutics Net Income
2030e1.26 B undefined575.37 M undefined489.65 M undefined
2029e755.18 M undefined331.54 M undefined739.12 M undefined
2028e433.25 M undefined196.65 M undefined188.35 M undefined
2027e227.35 M undefined86.31 M undefined104.36 M undefined
2026e0 undefined-27.03 M undefined-17.16 M undefined
2025e0 undefined-24.48 M undefined-17.16 M undefined
2024e0 undefined-22.34 M undefined-20.01 M undefined
20230 undefined-21.44 M undefined-17.19 M undefined
20220 undefined-24.82 M undefined-24.28 M undefined
20210 undefined-24.54 M undefined-24.46 M undefined
20200 undefined-31.68 M undefined-31.81 M undefined
20190 undefined-23 M undefined-23.25 M undefined
20180 undefined-14.06 M undefined-13.95 M undefined
20170 undefined-5 M undefined-4.95 M undefined
20160 undefined-5.08 M undefined-4.98 M undefined
20150 undefined-8.54 M undefined-8.49 M undefined
20140 undefined-7.42 M undefined-9.25 M undefined
20130 undefined-5.04 M undefined-4.9 M undefined
20120 undefined-3.52 M undefined-3.43 M undefined
20110 undefined-3.89 M undefined-3.92 M undefined
20100 undefined-2.59 M undefined-2.42 M undefined
20090 undefined-1.75 M undefined-1.78 M undefined
20080 undefined-3.27 M undefined-3.47 M undefined
20070 undefined-4.92 M undefined-6.24 M undefined
20060 undefined-2.88 M undefined-3.92 M undefined
20050 undefined-2.57 M undefined-2.6 M undefined

Brainstorm Cell Therapeutics Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00000000000000000000000.230.430.761.26
-----------------------90.7574.3666.23
--------------------------
00000000000000000000000000
-2-2-4-3-1-2-3-3-5-7-8-5-5-14-23-31-24-24-21-22-24-2786196331575
----------------------37.8945.2743.8445.82
-2-3-6-3-1-2-3-3-4-9-8-4-4-13-23-31-24-24-17-20-17-17104188739489
-50.00100.00-50.00-66.67100.0050.00-33.33125.00-11.11-50.00-225.0076.9234.78-22.58--29.1717.65-15.00--711.7680.77293.09-33.83
1.451.581.953.274.085.948.019.1710.7413.6618.4118.6618.782021.9129.8536.1836.5143.080000000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Brainstorm Cell Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Brainstorm Cell Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Brainstorm Cell Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Brainstorm Cell Therapeutics's financial health and stability.

Assets

Brainstorm Cell Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Brainstorm Cell Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Brainstorm Cell Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Brainstorm Cell Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200520062007200820092010201120122013201420152016201720182019202020212022
-2-3-6-3-1-2-3-3-4-9-8-4-4-13-23-31-24-24
000000000000000000
000000000000000000
00000000010-11010-6-32
123010211411111523
000000000000000000
000000000000000000
00-1-10-2-2-2-4-4-7-5-2-12-11-35-26-19
000000000000000000
0000000-22-4-1153-15-401
0000000-22-4-116406-401
000000000000000000
000000000000000000
001102453914001257660
002102453914001257660
------------------
000000000000000000
0000001020-301-1037-18-18
-1.05-1-2.12-1.88-0.74-2.08-2.27-3.03-4.16-4.65-7.46-5.96-2.54-12.76-11.72-35.57-26.6-19.35
000000000000000000

Brainstorm Cell Therapeutics stock margins

The Brainstorm Cell Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Brainstorm Cell Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Brainstorm Cell Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Brainstorm Cell Therapeutics's sales revenue. A higher gross margin percentage indicates that the Brainstorm Cell Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Brainstorm Cell Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Brainstorm Cell Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Brainstorm Cell Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Brainstorm Cell Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Brainstorm Cell Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Brainstorm Cell Therapeutics Margin History

Brainstorm Cell Therapeutics Gross marginBrainstorm Cell Therapeutics Profit marginBrainstorm Cell Therapeutics EBIT marginBrainstorm Cell Therapeutics Profit margin
2030e0 %45.85 %39.02 %
2029e0 %43.9 %97.87 %
2028e0 %45.39 %43.47 %
2027e0 %37.96 %45.9 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %

Brainstorm Cell Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Brainstorm Cell Therapeutics earnings per share therefore indicates how much revenue Brainstorm Cell Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Brainstorm Cell Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Brainstorm Cell Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Brainstorm Cell Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Brainstorm Cell Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Brainstorm Cell Therapeutics Revenue, EBIT and net profit per share

DateBrainstorm Cell Therapeutics Sales per ShareBrainstorm Cell Therapeutics EBIT per shareBrainstorm Cell Therapeutics Earnings per Share
2030e17.91 undefined0 undefined6.99 undefined
2029e10.78 undefined0 undefined10.55 undefined
2028e6.18 undefined0 undefined2.69 undefined
2027e3.24 undefined0 undefined1.49 undefined
2026e0 undefined0 undefined-0.24 undefined
2025e0 undefined0 undefined-0.24 undefined
2024e0 undefined0 undefined-0.29 undefined
20230 undefined-0.5 undefined-0.4 undefined
20220 undefined-0.68 undefined-0.67 undefined
20210 undefined-0.68 undefined-0.68 undefined
20200 undefined-1.06 undefined-1.07 undefined
20190 undefined-1.05 undefined-1.06 undefined
20180 undefined-0.7 undefined-0.7 undefined
20170 undefined-0.27 undefined-0.26 undefined
20160 undefined-0.27 undefined-0.27 undefined
20150 undefined-0.46 undefined-0.46 undefined
20140 undefined-0.54 undefined-0.68 undefined
20130 undefined-0.47 undefined-0.46 undefined
20120 undefined-0.38 undefined-0.37 undefined
20110 undefined-0.49 undefined-0.49 undefined
20100 undefined-0.44 undefined-0.41 undefined
20090 undefined-0.43 undefined-0.44 undefined
20080 undefined-1 undefined-1.06 undefined
20070 undefined-2.52 undefined-3.2 undefined
20060 undefined-1.82 undefined-2.48 undefined
20050 undefined-1.77 undefined-1.79 undefined

Brainstorm Cell Therapeutics business model

Brainstorm Cell Therapeutics Inc is an emerging biotech company based in New York City that focuses on developing novel therapies for the treatment of neurodegenerative diseases. The company was founded in 2002 by a team of leading scientists and experts in the field of stem cell research. Their goal was to advance the development of treatment options for diseases such as ALS (Amyotrophic Lateral Sclerosis), Multiple Sclerosis, and Parkinson's through innovative approaches to stem cell therapy. Brainstorm Cell Therapeutics' business model is based on the unique property of stem cells to differentiate into a variety of cell types and regenerate damaged tissue. The company harnesses this ability to develop tailored stem cell therapies that are customized to meet the specific needs of each patient. By utilizing the potential of stem cells to repair tissue damage and support the body's own healing process. The company is divided into two divisions: therapeutics and diagnostics. The therapeutics division is the core area, focusing on the development of stem cell therapies for the treatment of ALS, Multiple Sclerosis, Parkinson's, and other diseases. The company has developed an approach using autologous stem cells, where stem cells are extracted from the patient's own body to minimize the risk of rejection reactions. The company has already reached Phase II clinical trials and has demonstrated promising results from this innovative technology stem cell therapy for the treatment of ALS, as well as MS and Parkinson's. The diagnostics division of Brainstorm Cell Therapeutics focuses on the development of diagnostic tests to aid physicians in diagnosing patients with neurodegenerative diseases more quickly and accurately. One of the current developments is the NurOwn ALS diagnostic test, which is based on the impact of ALS on the patient's immune system. One of Brainstorm Cell Therapeutics' most well-known products is "NurOwn." This stem cell therapy product is provided to ALS patients. The product utilizes the patient's autologous stem cells to slow the progression of the disease and promote the growth of healthy tissue. It is a personalized therapy, tailored to the specific needs of each patient. The company has already conducted various clinical trials with NurOwn and achieved promising results. Brainstorm Cell Therapeutics is an innovative biotech company focused on the development of stem cell therapies for the treatment of neurodegenerative diseases. The company has already achieved promising results with its therapies and plans to further improve its product range. With a strong scientific team and innovative business model, it is well-positioned to play a leading role in the development of therapies for the treatment of neurodegeneration in the future. Brainstorm Cell Therapeutics is one of the most popular companies on Eulerpool.com.

Brainstorm Cell Therapeutics SWOT Analysis

Strengths

Brainstorm Cell Therapeutics Inc possesses several strengths that contribute to its success. These strengths include:

  • Advanced Technology: Brainstorm utilizes innovative technology in the field of stem cell research.
  • Strong Research Capability: The company has a team of skilled and experienced researchers who drive its scientific advancements.
  • Partnerships and Alliances: Brainstorm has established valuable collaborations with renowned institutions and organizations, enabling access to additional resources and expertise.
  • Intellectual Property: The company holds a portfolio of patents and proprietary technology, providing it with a competitive edge.

Weaknesses

Despite its strengths, Brainstorm Cell Therapeutics Inc also suffers from certain weaknesses, which may hinder its progress. These weaknesses include:

  • Financial Dependency: The company heavily relies on external funding to support its research and development efforts.
  • Limited Products: Brainstorm currently has a limited product pipeline, which may restrict its revenue potential.
  • Regulatory Challenges: The stringent regulations governing the development and commercialization of stem cell-based therapies could pose obstacles for Brainstorm.

Opportunities

Brainstorm Cell Therapeutics Inc has numerous opportunities for further growth and success. These opportunities include:

  • Increasing Demand: With the growing prevalence of neurological diseases, there is a rising demand for innovative therapies in this field, providing a significant market opportunity.
  • Global Expansion: Brainstorm can explore international markets and expand its reach to a broader patient population.
  • Collaborative Ventures: The company can pursue collaborative ventures with pharmaceutical companies or research institutions to accelerate product development.

Threats

Brainstorm Cell Therapeutics Inc faces various threats that could impact its future prospects. These threats include:

  • Competition: The stem cell therapy market is highly competitive, with the presence of established players and emerging startups.
  • Regulatory Hurdles: Stringent regulations and clinical trial requirements can significantly delay the approval and commercialization of Brainstorm's therapies.
  • Technological Advancements: Rapid advancements in stem cell research by competitors might outpace Brainstorm's progress, affecting its market position.

Brainstorm Cell Therapeutics valuation based on historical P/E ratio, EBIT, and P/S ratio.

Brainstorm Cell Therapeutics shares outstanding

The number of shares was Brainstorm Cell Therapeutics in 2023 — This indicates how many shares 43.076 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Brainstorm Cell Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Brainstorm Cell Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Brainstorm Cell Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Brainstorm Cell Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Brainstorm Cell Therapeutics Stock splits

In Brainstorm Cell Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.07 -0.05  (29.97 %)2024 Q1
9/30/2023-0.14 -0.14  (1.96 %)2023 Q3
6/30/2023-0.15 -0.27  (-76.47 %)2023 Q2
3/31/2023-0.17 -0.14  (16.82 %)2023 Q1
12/31/2022-0.15 -0.13  (12.1 %)2022 Q4
9/30/2022-0.18 -0.19  (-3.49 %)2022 Q3
6/30/2022-0.15 -0.19  (-27.01 %)2022 Q2
3/31/2022-0.13 -0.15  (-13.12 %)2022 Q1
12/31/2021-0.2 -0.17  (15.25 %)2021 Q4
9/30/2021-0.21 -0.15  (28.26 %)2021 Q3
1
2
3
4

Eulerpool ESG Scorecard© for the Brainstorm Cell Therapeutics stock

Eulerpool World ESG Rating (EESG©)

49/ 100

🌱 Environment

51

👫 Social

68

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Brainstorm Cell Therapeutics Stock Shareholders

%
Name
Stocks
Change
Date
4.37 % Ness (Kevin Dean)3,060,000-600,0002/14/2024
3.09 % Abbhi Investments LLC2,164,530010/31/2023
2.86 % ACC International Holdings, Ltd.2,000,84703/1/2024
2.03 % The Vanguard Group, Inc.1,423,310012/31/2023
1.20 % Lebovits Chaim843,565245,0724/18/2024
0.66 % BlackRock Institutional Trust Company, N.A.460,027-1,05612/31/2023
0.60 % Lindborg (Stacy R. Ph.D.)423,435241,9353/11/2024
0.51 % Geode Capital Management, L.L.C.357,04146,26412/31/2023
0.49 % Liberty Wealth Management, LLC340,150-12,46912/31/2023
0.28 % Weaver Consulting Group, LLC199,35603/31/2024
1
2
3
4
5
...
10

Brainstorm Cell Therapeutics Executives and Management Board

Mr. Chaim Lebovits52
Brainstorm Cell Therapeutics President, Chief Executive Officer
Compensation 1.12 M
Dr. Stacy Lindborg52
Brainstorm Cell Therapeutics Co-Chief Executive Officer
Compensation 851,543
Prof. Jacob Frenkel80
Brainstorm Cell Therapeutics Independent Chairman of the Board (since 2020)
Compensation 152,811
Dr. Irit Arbel62
Brainstorm Cell Therapeutics Independent Vice Chairman of the Board (since 2004)
Compensation 148,012
Ms. Alla Patlis36
Brainstorm Cell Therapeutics Chief Financial Officer, Controller
Compensation 80,000
1
2
3

Brainstorm Cell Therapeutics stock: Frequently Asked Questions

What values and corporate philosophy does Brainstorm Cell Therapeutics represent?

Brainstorm Cell Therapeutics Inc represents values such as innovation, integrity, and commitment to providing revolutionary treatments for neurological diseases. With a strong corporate philosophy focused on patient-centered care and scientific excellence, Brainstorm Cell Therapeutics Inc aims to improve the lives of individuals suffering from neurodegenerative conditions. Through their groundbreaking stem cell technology, the company strives to offer effective therapies that address the underlying causes of diseases like amyotrophic lateral sclerosis (ALS). With a relentless pursuit of advancements in regenerative medicine, Brainstorm Cell Therapeutics Inc aims to bring hope and optimize the potential for patients and their families.

In which countries and regions is Brainstorm Cell Therapeutics primarily present?

Brainstorm Cell Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Brainstorm Cell Therapeutics achieved?

Since its establishment, Brainstorm Cell Therapeutics Inc has accomplished several noteworthy milestones. Firstly, the company successfully developed its proprietary NurOwn® technology, a stem cell-based therapy platform for neurodegenerative diseases. Additionally, Brainstorm Cell Therapeutics Inc conducted phase 1 and phase 2 clinical trials, demonstrating the safety and efficacy of NurOwn® in treating patients with amyotrophic lateral sclerosis (ALS). The company received the prestigious designation of Fast Track status from the U.S. FDA for their ALS clinical development program. Furthermore, Brainstorm Cell Therapeutics Inc has gained recognition for its innovation and commitment to improving patients' lives within the field of cell therapy.

What is the history and background of the company Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics Inc. is a renowned biotechnology company specializing in the development of innovative cell-based therapies. Established in 2000, the company is dedicated to advancing treatments for neurodegenerative diseases, focusing primarily on amyotrophic lateral sclerosis (ALS). By harnessing the therapeutic potential of stem cells, Brainstorm Cell Therapeutics Inc. aims to revolutionize the field of regenerative medicine. With its cutting-edge proprietary platform, NurOwn®, the company has gained significant recognition for its groundbreaking research and clinical advancements. Brainstorm Cell Therapeutics Inc. has garnered a strong reputation in the industry, and its commitment to curing neurological disorders continues to drive its pioneering efforts.

Who are the main competitors of Brainstorm Cell Therapeutics in the market?

The main competitors of Brainstorm Cell Therapeutics Inc in the market include companies such as Pluristem Therapeutics Inc, Athersys, Inc, and Vericel Corporation. These companies, like Brainstorm Cell Therapeutics Inc, are focused on the development and commercialization of innovative cell-based therapies. However, Brainstorm Cell Therapeutics Inc distinguishes itself through its unique platform technology and proprietary stem cell therapy, NurOwn®, which has shown promising results in the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS).

In which industries is Brainstorm Cell Therapeutics primarily active?

Brainstorm Cell Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Brainstorm Cell Therapeutics?

The business model of Brainstorm Cell Therapeutics Inc revolves around developing and commercializing innovative autologous cellular therapies for neurodegenerative diseases. The company specializes in their proprietary NurOwn technology platform, which aims to harness the potential of adult stem cells for the treatment of diseases like Amyotrophic Lateral Sclerosis (ALS). Brainstorm's business model focuses on conducting clinical trials to demonstrate the safety and efficacy of their therapies, seeking regulatory approvals, and partnering with biopharmaceutical companies to bring their treatments to market globally. Through their research and development efforts, Brainstorm aims to provide cutting-edge therapies that address the unmet medical needs of patients facing neurodegenerative disorders.

What is the P/E ratio of Brainstorm Cell Therapeutics 2024?

The Brainstorm Cell Therapeutics P/E ratio is -0.9.

What is the P/S ratio of Brainstorm Cell Therapeutics 2024?

The Brainstorm Cell Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Brainstorm Cell Therapeutics?

The AlleAktien quality score for Brainstorm Cell Therapeutics is 5/10.

What is the revenue of Brainstorm Cell Therapeutics 2024?

The revenue cannot currently be calculated for Brainstorm Cell Therapeutics.

How high is the profit of Brainstorm Cell Therapeutics 2024?

The expected Brainstorm Cell Therapeutics profit is -20.01 M USD.

What is the business model of Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company based in the USA that focuses on developing novel therapies for neurological disorders. The company's business model involves identifying, developing, and marketing advanced treatment options for patients with severe neurological conditions. The company is divided into several business divisions, including research and development, clinical studies, manufacturing, sales, and marketing. The research and development unit is responsible for identifying and developing promising therapeutic approaches for conditions such as ALS and multiple sclerosis. The clinical study unit conducts clinical trials and tests to evaluate the efficacy and safety of new therapies, while the manufacturing unit is responsible for producing the therapy products. The main product of Brainstorm Cell Therapeutics Inc is NurOwn, an autologous cell therapy developed for the treatment of ALS (Amyotrophic Lateral Sclerosis). This technology utilizes the properties of mesenchymal stem cells to release specific growth factors that support the regeneration of neurons in the nervous system. NurOwn is based on a patented process for isolating and purifying mesenchymal stem cells, which are extracted from the patient's bone marrow and then proliferated in vitro. Brainstorm Cell Therapeutics Inc works closely with research organizations and medical institutions to promote the development and marketing of NurOwn and other therapeutic approaches. The company has established a strong partnership with Hadassah University Hospital in Israel, a leading medical research center known for its pioneering work in developing and applying novel therapies for ALS. The commercial strategy of Brainstorm Cell Therapeutics Inc includes marketing its products to medical professionals and relevant organizations in various European countries, including Germany, France, Italy, Spain, and the United Kingdom. The company is also working on expanding its presence in new markets and regions through strategic partnerships with other biopharmaceutical companies. Overall, Brainstorm Cell Therapeutics Inc aims to become a leading biopharmaceutical company for the development of cell therapies for neurological disorders. The company is actively working to demonstrate the potential of its innovative therapeutic approaches in treating ALS and other neurological conditions and to bring its products to new markets to help patients worldwide.

What is the Brainstorm Cell Therapeutics dividend?

Brainstorm Cell Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Brainstorm Cell Therapeutics pay dividends?

The dividend cannot currently be calculated for Brainstorm Cell Therapeutics or the company does not pay out a dividend.

What is the Brainstorm Cell Therapeutics ISIN?

The ISIN of Brainstorm Cell Therapeutics is US10501E2019.

What is the Brainstorm Cell Therapeutics WKN?

The WKN of Brainstorm Cell Therapeutics is A12BXW.

What is the Brainstorm Cell Therapeutics ticker?

The ticker of Brainstorm Cell Therapeutics is BCLI.

How much dividend does Brainstorm Cell Therapeutics pay?

Over the past 12 months, Brainstorm Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Brainstorm Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Brainstorm Cell Therapeutics?

The current dividend yield of Brainstorm Cell Therapeutics is .

When does Brainstorm Cell Therapeutics pay dividends?

Brainstorm Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Brainstorm Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Brainstorm Cell Therapeutics located?

Brainstorm Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Brainstorm Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Brainstorm Cell Therapeutics from 7/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/15/2024.

When did Brainstorm Cell Therapeutics pay the last dividend?

The last dividend was paid out on 7/15/2024.

What was the dividend of Brainstorm Cell Therapeutics in the year 2023?

In the year 2023, Brainstorm Cell Therapeutics distributed 0 USD as dividends.

In which currency does Brainstorm Cell Therapeutics pay out the dividend?

The dividends of Brainstorm Cell Therapeutics are distributed in USD.

Other fundamentals and analyses of Brainstorm Cell Therapeutics in the deep dive.

Our stock analysis for Brainstorm Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brainstorm Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.